Document Detail


Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
MedLine Citation:
PMID:  11226635     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The clinical significance and the effects of pharmacological treatment of patients with Alzheimer's disease (AD) were evaluated by measurement of acetylcholinesterase (AChE) in the cerebrospinal fluid (CSF). CSF-AChE of AD patients was lower, not significantly, compared with controls. However, CSF-AChE was significantly increased after treatment of AD patients with AChE inhibitors (donepezil and galantamine). The increase was higher in patients treated with donezepil than in those treated with galantamine, which might be related to different mechanisms for the substances. The increase was also dose-dependent, and was especially marked in patients showing a clinical response. These data suggest that CSF biomarkers are capable not only of identifying a biochemical effect of drugs, but also of differentiating between different compounds in a dose-dependent manner.
Authors:
P Davidsson; K Blennow; N Andreasen; B Eriksson; L Minthon; C Hesse
Related Documents :
19037815 - Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 pa...
2221845 - Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various ne...
501385 - Fibrin degradation products in the cerebrospinal fluid of patients with pneumococcal me...
23947935 - Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults ...
6448885 - Antidepressant potentiation of 5-hydroxytryptophan by l-deprenil in affective illness.
20639625 - Hemoglobin h disease in guangxi province, southern china: clinical review of 357 patients.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuroscience letters     Volume:  300     ISSN:  0304-3940     ISO Abbreviation:  Neurosci. Lett.     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-03-06     Completed Date:  2001-06-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7600130     Medline TA:  Neurosci Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  157-60     Citation Subset:  IM    
Affiliation:
Department of Clinical Neuroscience, Experimental Neuroscience section, Göteborg University, Sahlgrenska University Hospital, S-431 80, Mölndal, Sweden. pia.davidsson@neuro.gu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcholinesterase / cerebrospinal fluid*,  drug effects*
Aged
Aged, 80 and over
Alzheimer Disease / cerebrospinal fluid*,  drug therapy
Analysis of Variance
Biological Markers / cerebrospinal fluid
Cholinesterase Inhibitors / pharmacology*,  therapeutic use
Dose-Response Relationship, Drug
Female
Galantamine / pharmacology*,  therapeutic use
Humans
Indans / pharmacology*,  therapeutic use
Male
Middle Aged
Piperidines / pharmacology*,  therapeutic use
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Cholinesterase Inhibitors; 0/Indans; 0/Piperidines; 120011-70-3/donepezil; 357-70-0/Galantamine; EC 3.1.1.7/Acetylcholinesterase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Distribution of novel RFamide-related peptide-like immunoreactivity in the mouse central nervous sys...
Next Document:  Neurodevelopmental consequences of gestational exposure (GD14-GD20) to low dose deltamethrin in rats...